Columvi is a CD20xCD3 T-cell engaging bispecific antibody. Columvi was the first fixed-duration bispecific antibody to receive accelerated approval by the FDA and conditional marketing authorisation in Europe to treat people with R/R DLBCL after two or more lines of systemic therapy. Columvi is approved in more than 50 countries for 3L+ DLBCL.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.